BCYC News and Press, Bicycle Therapeutics plc From 11/13/19

- BT5528 targets EphA2, an antigen believed to be overexpressed in tumor types with high unmet need and a target for which antibody-based approaches have been unsuccessful to date - Phase I dose escalation has commenced in the U.S and will be conducted at sites in both the U.S. and UK ...

Bicycle Therapeutics (NASDAQ: BCYC ): Q3 GAAP EPS of -$0.53 misses by $0.07 . More news on: Bicycle Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...

- BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies - Preclinical data on Bicycle® tumor-targeted immune cell agonists to be presented at SITC Annual Meeting on November 9, 2019 - Cash was $96.0 million at September 30, 2019, which exclu...

- BT7480 has been selected as the Company’s lead immuno-oncology candidate to advance into IND-enabling studies Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bic...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the appointment of Veronica Jordan, Ph.D., to its Board of Directors, where she ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the appointment of Nigel Crockett, Ph.D., as the company’s Chief Business...

Bicycle to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and CNS drug development Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on ...

Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycles® ) product platform, today announced that new translational data for BT1718 and preclinical data...

- Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models - Early analysis of data shows stable disease in 54% of evaluable patients at eight weeks, across all cohorts of the all-comers Phase I escalation - Tumor biopsies indicate ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycles ® ) product platform, today announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evalua...